Piper Sandler raised the firm’s price target on Tempus AI to $105 from $70 and keeps a Neutral rating on the shares. The firm surveyed 59 oncologists to gauge their views on profiling and market share. Overall, Piper thinks the survey is positive for companies such as Guardant Health (GH) and Tempus AI (TEM). The firm sees liquid biopsy as growing even faster than CGP, and saw significant interest in it among different use cases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Goldman downgraded, Coinbase initiated: Wall Street’s top analyst calls
- Tempus AI, Inc. Class A: Downgrade to Hold Amid Balanced Valuation and Strong Market Positioning
- Tempus AI downgraded to Hold from Buy at TD Cowen
- AI Daily: Nvidia, TSMC unveil first Blackwell wafer produced in U.S.
- tempus AI Inc Class A call volume above normal and directionally bullish